<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03680716</url>
  </required_header>
  <id_info>
    <org_study_id>CER 2018-01163</org_study_id>
    <nct_id>NCT03680716</nct_id>
  </id_info>
  <brief_title>Combined Saphenous Nerve and IPACK Blocks Versus Infiltration Analgesia After Anterior Cruciate Ligament Reconstruction</brief_title>
  <official_title>Analgesic Efficacy of a Combined Saphenous Nerve Block and IPACK Block Versus Local Infiltration Analgesia After Anterior Cruciate Ligament Reconstruction: a Randomized Controlled Double-blinded Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A lot of patient have posterior knee pain after ACL reconstruction despite saphenous nerve
      block. Recently a new block has been described, know as IPACK block (interspace between the
      popliteal artery and the capsule of the posterior knee). The objective of this randomized
      controlled double-blinded trial is to assess whether a combined saphenous nerve block with
      IPACK block is more effective for the postoperative pain than a local infiltration analgesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The saphenous nerve and the iPACK will be performed after general anaesthesia induction and
      before the surgery under ultrasound-guidance.

      The local infiltration analgesia will be performed by the surgeon during the surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total morphine consumption (mg)</measure>
    <time_frame>24 hours postoperatively</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total morphine consumption (mg)</measure>
    <time_frame>2 hours, 48 hours and 72 hours postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores (numeric rating scale, 0-10) at rest and on movement</measure>
    <time_frame>2hours, 24hours, 48hours and 72hours postoperatively</time_frame>
    <description>0= no pain, 10=the worst pain imaginable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of postoperative nausea and vomiting</measure>
    <time_frame>2hours, 24hours, 48hours and 72hours postoperatively</time_frame>
    <description>Yes/No</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of antiemetic consumption</measure>
    <time_frame>2hours, 24hours, 48hours and 72hours postoperatively</time_frame>
    <description>Yes/No</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of pruritus</measure>
    <time_frame>2hours, 24hours, 48hours and 72hours postoperatively</time_frame>
    <description>Yes/No</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Active flexion</measure>
    <time_frame>24hours, 48hours and 72hours postoperatively</time_frame>
    <description>Flexion of the knee by the patient measured in degrees</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quadriceps muscle strength (numeric scale, 1-5)</measure>
    <time_frame>24hours, 48hours and 72hours postoperatively</time_frame>
    <description>1=no contraction, 5=normal strength</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distance walked (meters)</measure>
    <time_frame>24 hours, 48hours and 72hours postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anterior Cruciate Ligament - Return to Sport after Injury survey</measure>
    <time_frame>4 and 8 postoperative months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Knee Documentation Committee score</measure>
    <time_frame>4 and 8 postoperative months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Postoperative Pain</condition>
  <condition>Anterior Cruciate Ligament Injury</condition>
  <condition>Anterior Cruciate Ligament Rupture</condition>
  <arm_group>
    <arm_group_label>IPACK block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saphenous nerve block and IPACK block by anesthetist under ultrasound guidance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Local infiltration analgesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Periarticular infiltration by surgeon</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine injection</intervention_name>
    <description>Saphenous nerve block with 20ml of ropivacaine 0.5% and IPACK block with 30ml of ropivacaine 0.2% (total dose of 160 mg).</description>
    <arm_group_label>IPACK block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine injection</intervention_name>
    <description>Periarticular infiltration of 80 ml ropivacaine 0.2% (total dose of 160mg).</description>
    <arm_group_label>Local infiltration analgesia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Statut ASA I-III.

          -  Patient scheduled for anterior crutiate ligament reconstruction under general
             anesthesia.

        Exclusion Criteria:

          -  Pregnancy.

          -  Contraindication to local anesthesia.

          -  Patient with chronic pain, opioid consumption or alcohol consumption.

          -  Patient with coagulation trouble, hepatic dysfunction or renal dysfunction.

          -  Patient with diabetic or femoral neuropathy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eric Albrecht, PD Dr</last_name>
    <phone>+41 79 556 63 41</phone>
    <email>eric.albrecht@chuv.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Anesthesia, Centre Hospitalier Universitaire Vaudois and University of Lausanne</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Albrecht, MD</last_name>
      <phone>+41795566341</phone>
      <email>eric.albrecht@chuv.ch</email>
    </contact>
    <contact_backup>
      <last_name>Istvan Bathory, MD</last_name>
      <phone>+41795565312</phone>
      <email>istvan.bathory@chuv.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Eric Albrecht, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 20, 2018</study_first_submitted>
  <study_first_submitted_qc>September 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2018</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Eric Albrecht</investigator_full_name>
    <investigator_title>Program director of regional anaesthesia</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rupture</mesh_term>
    <mesh_term>Anterior Cruciate Ligament Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

